A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Andecaliximab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 02 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2017 Planned End Date changed from 1 May 2019 to 1 Nov 2018.
- 12 Dec 2017 Planned primary completion date changed from 1 May 2019 to 1 Nov 2018.